摘要
目的探讨归肺理气方结合定向透药疗法治疗急性加重期慢性阻塞性肺疾病(AECOPD)痰热壅肺证的临床疗效。方法选取2018年5月—2019年6月诊治的72例AECOPD痰热壅肺证患者,按区组随机化分为A组和B组,每组均36例。均给予指南常规治疗,A组给予中药归肺理气方内服治疗,B组给予归肺理气方内服结合定向透药疗法治疗。治疗前和治疗14 d后进行相关检查并比较,评估临床疗效和安全性。结果B组治疗总显效率75.00%(27/36)显著高于A组50.00%(18/36)(P<0.05);两组治疗后“咳嗽”“喘息”“胸闷”和“痰量”积分与治疗前比较,均明显下降(P<0.05),B组治疗后“咳嗽”“痰量”积分明显低于A组(P<0.05);两组治疗后PaPO_(2)、PaPO_(2)、SaO_(2)、FVC、FEV1、FEV1%与治疗前比较,均有明显改善(P<0.05),其中B组治疗后PaPO_(2)显著低于A组,FEV1、FEV1%明显高于A组,差异有统计学意义(P<0.05);两组均未出现严重不良反应。结论归肺理气方内服结合定向透药疗法治疗AECOPD痰热壅肺证疗效显著,能有效缓解患者的临床症状,改善肺通气功能,且安全性好。
Objective To investigate the clinical efficacy of Guifei Liqi Decoction(归肺理气方)combined with directional drug penetration therapy in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD)with phlegm-heat obstructing lung syndrome.Methods Seventy-two AECOPD patients with phlegm-heat obstructing lung syndrome from May 2018 to June 2019 were randomly divided into group A and group B,36 cases in each group.The patients in group A were treated with Guifei Liqi Decoction and group B were treated with Guifei Liqi Decoction combined with directional drug penetration therapy.Before and 14 days after treatment,relevant examinations were conducted and compared to evaluate the clinical efficacy and safety.Results The total effective rate was 75.00%(27/36)in group B,which was significantly higher than 50.00%(18/36)in group A(P<0.05).The scores of“cough”,“wheezing”,“chest tightness”and“sputum volume”in two groups after treatment were significantly lower than those before treatment(P<0.05),and the scores of“cough”and“sputum volume”in group B were significantly lower than those in group A(P<0.05).After treatment,PaPO_(2),PaPO_(2),SaO_(2),FVC,FEV1 and FEV1%in the two groups were significantly improved compared with those before treatment(P<0.05).PaPO_(2)in group B was significantly lower than that in group A,and FEV1 and FEV1%in group B were significantly higher than those in group A(P<0.05).There were no serious adverse reactions in both groups.Conclusion Guifei Liqi Decoction combined with directional drug penetration therapy has a significant effect on AECOPD with phlegm-heat obstructing lung syndrome.It can effectively relieve the clinical symptoms of patients,improve pulmonary ventilation function,and has good safety.
作者
董文敏
陈颖
堵玉萍
DONG Wenmin;CHEN Ying;DU Yuping(Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Shanghai Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200082,China)
出处
《辽宁中医杂志》
CAS
2022年第2期82-85,共4页
Liaoning Journal of Traditional Chinese Medicine
基金
上海中医药大学预算内科研项目(18LK073)
上海市中医药新兴交叉学科资助计划建设项目(18ZYYJCXK-136)
上海市“医苑新星”青年医学人才培养资助计划(2019YXRC06-18)
关键词
慢性阻塞性肺疾病
痰热壅肺证
归肺理气方
内服
定向透药疗法
肺功能
chronic obstructive pulmonary disease
phlegm-heat obstructing lung syndrome
Guifei Liqi Decoction(归肺理气方)
oral administration
directional drug penetration therapy
lung function
作者简介
董文敏(1992-),女,内蒙古集宁人,初级医师,硕士,研究方向:中西医结合临床药学与制剂研究;通讯作者:堵玉萍(1967-),女,上海人,副主任医师,学士,研究方向:中西医结合肺病治疗学。E-mail:sky_shanghai@163.com。
